Twist Bioscience
Twist Bioscience secures $120M Series D for biotech innovation
Quick Facts
Twist Bioscience Secures $120M to Transform Biotech Industry
Twist Bioscience has successfully raised $120M in Series D funding, marking a significant milestone in the company's growth journey. This latest investment brings the company's total funding to $350M and establishes a $1.5B valuation.
Company Background
Founded in 2013 and headquartered in South San Francisco, CA, Twist Bioscience has emerged as a leader in Synthetic biology company manufacturing DNA sequences. With a team of 500+ dedicated professionals, the company has built a reputation for innovation and customer-centric solutions.
Business Model Innovation
Biotechnology platform providing synthetic DNA manufacturing for research and applications
The company's approach has resonated strongly with customers and investors alike, demonstrating sustainable growth and market validation across multiple metrics.
Market Opportunity
The market for Twist Bioscience's solutions represents a significant opportunity, with increasing demand driven by digital transformation trends and evolving customer expectations.
Industry Dynamics
- Digital Adoption: Accelerating shift toward digital-first solutions
- Customer Expectations: Rising demand for seamless, efficient experiences
- Market Consolidation: Opportunity for technology leaders to capture market share
- Innovation Imperative: Need for continuous technological advancement
Funding Round Analysis
This Series D represents more than just capital injection—it's a strategic partnership that will accelerate Twist Bioscience's mission and expand its market reach.
Strategic Value
The funding provides Twist Bioscience with the resources necessary to:
- Scale Operations: Expanding team and operational capacity
- Enhance Technology: Investing in platform capabilities and innovation
- Market Expansion: Growing presence in new geographic and vertical markets
- Customer Success: Improving customer experience and support capabilities
Investor Confidence
The successful completion of this funding round demonstrates strong investor confidence in Twist Bioscience's vision, execution capabilities, and market opportunity.
Technology Platform
Twist Bioscience has built a robust technology platform that serves as the foundation for its competitive advantage and growth strategy.
Platform Capabilities
- Scalable Architecture: Built for enterprise-grade performance and reliability
- Integration Ecosystem: Seamless connectivity with existing business systems
- Data Analytics: Advanced insights and reporting capabilities
- Security & Compliance: Enterprise-grade security and regulatory compliance
Innovation Focus
The company continues to invest heavily in research and development, ensuring its platform remains at the forefront of technological advancement and industry best practices.
Competitive Positioning
Twist Bioscience has established a strong competitive position through its focus on innovation, customer success, and market expertise.
Competitive Advantages
- Market Leadership: Strong position in target market segments
- Technology Differentiation: Unique capabilities and innovative features
- Customer Relationships: Strong customer satisfaction and retention rates
- Team Expertise: Deep industry knowledge and technical capabilities
Growth Strategy
With this latest funding, Twist Bioscience is well-positioned to execute on an ambitious growth strategy that includes market expansion, product development, and strategic partnerships.
Strategic Priorities
- Product Innovation: Continued investment in platform enhancement and new features
- Market Penetration: Expanding customer base within existing markets
- Geographic Expansion: Entering new geographic markets and regions
- Partnership Development: Strategic alliances and ecosystem partnerships
Operational Excellence
The company plans to invest in operational infrastructure and capabilities to support sustained growth while maintaining high levels of customer satisfaction and service quality.
Financial Performance
While specific financial metrics are not disclosed, the company's ability to raise $120M at a $1.5B valuation indicates strong financial performance and growth trajectory.
Key Metrics
- Revenue Growth: Demonstrating consistent growth in recurring revenue
- Customer Acquisition: Expanding customer base across target segments
- Market Share: Growing presence in addressable market
- Unit Economics: Healthy customer acquisition costs and lifetime value metrics
Future Outlook
The successful completion of this funding round positions Twist Bioscience for continued growth and market leadership. The company's focus on innovation, customer success, and operational excellence provides a strong foundation for future expansion.
Long-term Vision
Twist Bioscience is committed to transforming the biotech industry through technology innovation and customer-centric solutions. The company's long-term vision includes becoming the leading platform in its market category while expanding into adjacent markets and geographies.
Market Impact
As Twist Bioscience continues to grow and innovate, the company is positioned to drive significant positive impact across its industry, helping customers achieve better outcomes while creating value for stakeholders.
This funding round represents an important milestone in Twist Bioscience's journey, providing the resources and strategic support needed to accelerate growth and achieve its ambitious goals.
Key Investors
About the Author

Related Company Reports
BioAge Therapeutics Raises $350M Series C to Transform Healthcare
BioAge Therapeutics secures $350M in Series C funding at $4.3B valuation to advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies.
NanoMedicine Labs Raises $460M Series C to Transform Healthcare
NanoMedicine Labs secures $460M in Series C funding at $5.8B valuation to advance phase iii clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases.
NeuroPharma raises $190M Series B in September 2025 funding round
NeuroPharma secures $190M in Series B funding in September 2025, reaching $1.6B valuation to advance its neurological drug discovery using ai and machine learning.
